Related Experiment Video
Updated: May 27, 2026
06:47
ABCG5/G8 Crystallization in a Lipidic Bicelle Environment for X-Ray Crystallography
Published on: August 25, 2023
Gout, genetics and ABC transporters.
Agnès Basseville1, Susan E Bates
1Molecular therapeutics section, Medical Oncology Branch, National Cancer Institute, Building 10 - Room 13N248, National Institutes of Health 9000 Rockville Pike, Bethesda, MD 20892 USA.
F1000 Biology Reports
|November 9, 2011
Summary
Genetic factors influence gout, a chronic arthritis. A specific ATP-binding cassette transporter isoform G2 (ABC G2) variant impairs urate elimination, suggesting new therapeutic targets for gout.
Area of Science:
- Genetics
- Nephrology
- Rheumatology
Background:
- Gout is a chronic arthritic condition linked to elevated blood urate levels.
- Recent research has identified genetic factors contributing to gout.
- A specific polymorphism in the ATP-binding cassette transporter isoform G2 (ABC G2) gene is a key genetic factor.
Purpose of the Study:
- To investigate the role of ABC G2 variants in gout pathogenesis.
- To understand the functional consequences of the Q141K polymorphism in ABC G2.
- To explore potential therapeutic strategies targeting ABC G2 for gout treatment.
Main Methods:
- Genetic analysis to identify ABC G2 polymorphisms.
- Functional assays to assess urate transport activity of ABC G2 variants.
- Cellular studies to evaluate protein trafficking and localization.
Main Results:
- The Q141K polymorphism in ABC G2 was identified as a significant genetic factor in gout.
- This variant reduces urate efflux by twofold due to impaired trafficking and intracellular retention.
- Wild-type ABC G2 protein is correctly expressed on the cell surface.
Conclusions:
- The Q141K variant of ABC G2 contributes to gout by impairing renal urate excretion.
- Strategies aimed at improving ABC G2 folding, trafficking, and function are promising therapeutic avenues for gout.
- Targeting ABC G2 offers a potential new approach for managing gout.
Related Concept Videos
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:31ABC Transporters: Exporter
ATP-binding cassette or ABC transporter is the largest superfamily of integral membrane proteins. The transporters have transmembrane-binding domains (TMDs) and nucleotide-binding domains (NBDs). The TMDs are specific to their substrates, whereas the NBDs are similar to engines that complete ATP hydrolysis to complete the substrate transport. They can be full transporters consisting of two TMDs and NBDs, half transporters with one TMD and NBD, while some encoded with a single TMD or NBD are...
01:27ABC Transporters: Importer
ATP-binding cassette or ABC transporters are a class of ATP-driven pumps that hydrolyze ATP to move solutes across the membrane. They can be grouped into importers and exporters. While exporters are present in all domains of life, importers exist only in bacteria and some plants.
In bacteria, based on the number of transmembrane helices and the chemical nature of their substrates, the ABC importers can be divided into three types:
In bacteria, based on the number of transmembrane helices and the chemical nature of their substrates, the ABC importers can be divided into three types:
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...